Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759
AQC
0.015
200%
BMO
0.001
-50%
YRL
0.18
102.2%
BOT
0.155
-50%
PFE
0.023
91.7%
IPB
0.005
-44.4%
FAL
0.375
87.5%
CDE
0.023
-39.5%
LKO
1.38
84%
BMG
0.007
-36.4%
ICR
0.014
75%
LIC
4.57
-35.1%
ATH
0.015
66.7%
AKN
0.004
-33.3%
QXR
0.005
66.7%
ECT
0.002
-33.3%
RMI
0.02
66.7%
PNT
0.01
-33.3%
WR1
0.23
58.6%
LOC
0.13
-25.7%
NGY
0.031
55%
BLZ
0.003
-25%
ALR
0.003
50%
GTR
0.003
-25%
AUK
0.003
50%
UNT
0.006
-25%
JAY
0.003
50%
URF
0.32
-22.9%
KCC
0.06
50%
W2V
0.007
-22.2%
SFM
0.21
50%
CPO
0.011
-21.4%
DY6
0.3
46.3%
SKM
0.19
-20.8%
IBX
0.016
45.5%
OLY
0.12
-20%
PGY
0.013
44.4%
ORD
0.32
-20%
RDG
0.01
42.9%
HMX
0.029
-19.4%
